Graphique 1 - Faculté de Médecine et de Pharmacie de Fès
Graphique 1 - Faculté de Médecine et de Pharmacie de Fès
Graphique 1 - Faculté de Médecine et de Pharmacie de Fès
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
209. S Koskenmies, TM Järvinen, P Onkamo, J Panelius, U Tuovinen, THasan,<br />
A Ranki, U Saarialho-Kere. Clinical and laboratory characteristics of<br />
Finnish Lupus erythematosus patients with cutaneous manifestations. Lupus<br />
(2008) 17: 337-347.<br />
210. Bro<strong>de</strong>r A, Putterman C. The prevalence of antiphospholipid antibody (aPL Ab)<br />
subtypes in SLE and CVA patients in: The 9th International Congress on SLE<br />
June 24 -27 2010, Vancouver, Canada in: Lupus 2010; 19: 1.<br />
211. M. Soubrier, S. Mathieu, JJ Dubost. Athérome <strong>et</strong> lupus erythémateux<br />
systémique. Revue du Rhumatisme 74 (2007) 1235–1239.<br />
212. Bosly A. Anticorps monoclonal anti-CD20 (rituximab) dans les maladies<br />
hématologiques <strong>et</strong> les affections auto-immunes. Réanimation Vol 15 - n° 4 - août<br />
2006 ;p 243-327.<br />
213. Go<strong>de</strong>au B, Bussone G , Hachulla E , Sibilia J, Michel M, , Guillevin L, Mouthon<br />
L. Rituximab <strong>et</strong> traitement <strong>de</strong>s maladies auto-immunes <strong>et</strong> inflammatoires<br />
systémiques. La Presse Médicale Vol 38 - n° 5 - mai 2009 ;p 691-859.<br />
214. Ba<strong>de</strong>r-Meunier B, Leverger G. Anémies hémolytiques auto-immunes<br />
chroniques <strong>de</strong> l’enfant : vers <strong>de</strong> nouvelles approches thérapeutiques ?<br />
Session : Epidémiologie <strong>et</strong> prise en charge <strong>de</strong>s anémies hémolytiques aigues<br />
<strong>et</strong> chroniques <strong>de</strong> l’enfant/ Archives <strong>de</strong> pédiatrie 13(2006)511-521.<br />
215. Papo T. Immunoglobulines polyvalentes par voie intraveineuse dans le lupus<br />
systémique. Rev Méd Interne 1999 ; 20 suppl 4 :414-8.<br />
216. LimVS, DeGowin RL, Zavala D, <strong>et</strong> al. Recombinant human erythropoi<strong>et</strong>in<br />
treatment in pre-dialysis patients. Ann Intern Med 1989;110:108–114.<br />
217. Ng T, Marx G, Littlewood T, <strong>et</strong> al. Recombinant erythropoi<strong>et</strong>in in clinical<br />
practice. Postgrad Med J 2003;79:367–376.<br />
218. King KE and Ness PM. Treatment of autoimmune hemolytic anemia. Semin<br />
Hematol 2005;42:131–136.<br />
219. Priofsky B. Immune haemolytic disease: the autoimmune haemolytic anemias.<br />
Clin Haematol 1975;4:167–180.<br />
220. L<strong>et</strong>chumanan P, Thumboo J. Danazol in the treatment of systemic lupus<br />
erythematosus: A qualitative systematic review. Semin Arthritis Rheum<br />
xx:xxx (article in press 2010)<br />
221. Tokunaga M, Fujii K, Saito K, <strong>et</strong> al. Down-regulation of CD40 and CD80 on B<br />
cells in patients with life-threatening systemic lupus erythematosus after<br />
successful treatment with rituximab. Rheumatology (Oxford) 2005;44:176–<br />
182.<br />
209